🟢 Eupraxia Pharmaceuticals is trading 8% up today in pre-market after Q2 EPS beat

Eupraxia Pharmaceuticals is trading $7.00 (+8.02%) in pre-market after reporting Q2 EPS of $(0.23), beating the $(0.25) estimate.

• Management reported $133.7 million in liquidity and expects existing cash reserves to fund operations into the second half of 2028.
• Investors may also be responding to positive EP-104GI data and planned Q4 2026 RESOLVE data.